Viking Therapeutics: A Study in Uncertain Ascent

The analysts, those detached observers of fortune, assign an average price target of $93.39. A number, ostensibly, derived from complex models and meticulous calculations. But one wonders if these projections aren’t merely an exercise in wishful thinking, a desperate attempt to impose order on a fundamentally chaotic system. Can Viking Therapeutics truly soar, or is this simply a mirage, a fleeting illusion destined to dissolve upon closer inspection?








